Mergers & Acquisitions Mergers & Acquisitions

Illumina customers questioned by EU regulator on impact of Grail acquisition

By Natalie McNelis
  • 28 Jun 2021 07:34
  • 28 Jun 2021 07:34
Illumina customers have been asked questions about the implications of the company’s $8 billion swoop for cancer-testing company Grail as part of the EU investigation of the deal, MLex has learned. 

The questions indicate that the European Commission is concerned about Illumina’s ability and incentive to deny downstream companies access to

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News